Highlights Xenon Pharmaceuticals Inc.

Equities

XENE

CA98420N1050

Real-time Estimate Cboe BZX Other stock markets 11:12:10 2024-04-30 am EDT			5-day change	1st Jan Change
42.14 ^USD	-1.37%		+2.39%	-8.66%

Apr. 19	Xenon Pharmaceuticals Inc. Announces Board Resignations	CI
Mar. 11	Transcript : Xenon Pharmaceuticals Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 11:20 AM

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Xenon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Xenon Pharmaceuticals Q4 Net Loss Widens	Feb. 29	MT
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-Of-Concept X-Nova Clinical Trial of Xen1101 in Major Depressive Disorder	Nov. 27	CI
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Xenon Pharmaceuticals Announces Publication of Results from Xen1101 Phase 2B "X-Tole" Clinical Trial in Peer-Reviewed Journal Article in Jama Neurology	23-10-09	CI
Xenon Pharmaceuticals Inc. Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress	23-09-04	CI
Xenon Pharmaceuticals Q2 Net Loss Widens	23-08-09	MT
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Xenon Pharmaceuticals' Q1 Loss Widens	23-05-10	MT
Xenon Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-01	CI
Xenon Pharmaceuticals' Q4 Loss Widens	23-03-01	MT
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-01	CI
Earnings Flash (XENE) XENON PHARMACEUTICALS Reports Zero Q4 Revenue vs. Street Est of $2.46M	23-03-01	MT
Xenon Pharmaceuticals Inc. Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)	22-12-02	CI
Xenon Pharmaceuticals Q3 Loss Widens, Revenue Drops	22-11-08	MT
Xenon Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
Earnings Flash (XENE) XENON PHARMACEUTICALS Reports Q3 Revenue $132,000	22-11-08	MT
Xenon Pharmaceuticals Inc. Announces Launch of XEN1101 Phase 3 Program with Initiation of X TOLE2 Clinical Trial in Patients with Focal Onset Seizures	22-11-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Xenon Pharmaceuticals Inc.

Equities

XENE

CA98420N1050

Highlights

Filters